[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"skin-ageing\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:skin-ageing":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,51,87,118],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100651900","skin-type-determination-using-image-artificial-intelligence-100651900",false,"NCT07765303","Skin Type Determination Using Image Artificial Intelligence","Skin Pigment Type, Phototype and Photodamage Determination Using Image Analyses Powered by Artificial Intelligence - SPAI Study","SPAI","Inclusion Criteria:\n\n* Aged 18 years or older\n* Able and willing to provide informed consent (oral or written, according to local regulations)\n* Willing to complete the study questionnaire\n* Willing to undergo non-invasive skin imaging and skin characteristic assessments of predefined sites on the upper arm and forearm\n\nExclusion Criteria:\n\n* Younger than 18 years of age\n* Unable to provide informed consent\n* Unable to complete study procedures\n* Tattoos, prominent scars, wounds, skin lesions, dressings, or other identifiable features at the predefined imaging sites that may interfere with image acquisition, assessment quality, or participant anonymity",true,"ALL","18 Years",{"count":21,"type":22},1500,"ESTIMATED","1 Day","OBSERVATIONAL","Skin color, how easily a person burns or tans in the sun (skin phototype), and the amount of chronic sun damage in the skin are important factors in skin health. These characteristics influence a person's risk of skin cancer, how skin diseases appear, how well treatments work, and how accurately doctors and artificial intelligence (AI) systems can diagnose skin conditions. However, current methods for classifying these characteristics are often imprecise and rely heavily on subjective assessments. As a result, both healthcare professionals and patients may incorrectly classify skin type, which can lead to inaccurate risk assessments and less personalized care.\n\nThis study aims to develop and validate AI algorithms that can accurately classify skin pigmentation, skin phototype, and accumulated sun damage using photographs of the skin. Unlike existing approaches, the study combines several different methods to create a more objective \"ground truth\" for training the AI. These methods include skin color measurements using spectrophotometry or colorimetry, assessments using the Monk Skin Tone Scale, questionnaires about sun sensitivity, and clinical evaluations by trained observers. By combining these data sources, the researchers hope to create a more reliable and scientifically robust classification system.\n\nThe study will recruit adults aged 18 years and older from several countries, including countries from all continents. Participants will complete a questionnaire about their skin, propensity to burn and sun exposure history. Researchers will then take standardized close-up and dermoscopic images of the skin on the arm and forearm, measure skin pigmentation using objective instruments when available, and assess skin phototype and sun damage. No invasive procedures will be performed, and no personally identifiable information will be collected.\n\nThe collected images and measurements will be used to train deep learning AI models. The researchers aim to develop algorithms that can classify skin pigmentation with at least 85% accuracy, skin phototype with at least 75% accuracy, and sun damage with at least 80% accuracy compared with the combined reference assessments. The algorithms will then be tested in independent datasets, including large dermatology image databases from Sweden, to evaluate how well they perform in different populations.\n\nThe study has several potential benefits. More accurate classification of skin characteristics could improve personalized skin cancer risk assessments and allow prevention advice to be tailored to individual needs. This may help identify people who would benefit from closer surveillance and stronger sun protection recommendations while avoiding unnecessary restrictions for people at lower risk. Improved classification could also enhance the diagnosis and management of inflammatory skin diseases and skin cancers, which can appear differently in people with different skin tones.\n\nAn additional goal is to address known biases in dermatology AI systems, which often perform less accurately in individuals with darker skin. By including participants with a wide range of skin tones and backgrounds, the researchers aim to contribute to the benchmarking of AI-driven medical devices wich hopefully can result in the development of fairer and more equitable AI tools.\n\nThe study involves minimal risk. Only photographs of the arm and forearm will be taken, and researchers will avoid capturing tattoos, prominent scars, or other identifying features. All data will be stored securely and only accessible to authorized researchers. The potential benefits of improving skin disease diagnosis, skin cancer prevention, and fairness in medical AI are considered to outweigh the small privacy risks associated with participation.",[27,28],"Skin Ageing","Skin",[30,31,32,33,34,35,36,37],"skin tone","pigmentation","skin color","chronic sun damage","photodamage","sun sensitivity","phototype","Fitzpatrick type","RECRUITING","2026-08-10",{"date":41,"type":42},"2026-08-14","ACTUAL",{"date":44,"type":42},"2025-04-28",{"date":46,"type":22},"2028-12-31",{"name":48,"class":49},"Region Skane","OTHER",11,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":58,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":4,"studyType":63,"phases":64,"briefSummary":66,"conditions":67,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":4},"100629312","efficacy-of-a-combined-oral-and-topical-collagen-regimen-compared-to-topical-collagen-or-oral-collagen-regimens-in-women-with-skin-ageing-signs-100629312","NCT07473037","Efficacy of a Combined Oral and Topical Collagen Regimen Compared to Topical Collagen or Oral Collagen Regimens in Women With Skin Ageing Signs","Evaluation of the Efficacy of an in and Out Collagen Routine Versus the Serum Alone and Versus the Oral Supplement Alone in Women With Skin Ageing Signs","Inclusion Criteria:\n\n* Participant having signed an Informed Consent Form (ICF) before any trial related activity is carried out;\n* Female participant;\n* Participant with a Fitzpatrick skin type I to III;\n* Participant aged 45 to 60 years inclusive at the time of signing the ICF;\n* Participant with a BMI ≥20 and \\\u003C 29 kg\u002Fm²;\n* Participant presenting:\n* Cheek firmness score ≥3 and ≤6 on the 10-point scale;\n* Crow's feet wrinkle score ≥2 and ≤4 on the L'Oréal Atlas;\n* Global facial wrinkle score ≥3 and ≤6 on the 10-point scale.\n* Female participant of childbearing potential must use one of the reliable methods of contraception during the investigation and agree not to change it during the study;\n\nA woman is considered of childbearing potential unless she is:\n\n* Postmenopausal for at least 12 months prior to screening visit;\n* Without uterus and\u002For both ovaries;\n* Has been surgically sterile for at least 6 months prior to Screening visit.\n* Participant must agree to use only the designated products\n* Participant willing and able to comply with all study procedures, lifestyle and dietary restrictions, and complete the entire study period\n* Participant affiliated to a health social security system (according to French Law).\n\nExclusion Criteria:\n\n* Participant who is pregnant or who is breast feeding;\n* Participant receiving hormone replacement therapy (HRT).\n* Participant who smokes more than two cigarettes per week;\n* Participant whose alcohol intake exceeds 2 drinks per week;\n* Participant with any uncontrolled diseases such as diabetes, hypertension, hyperthyroidism or hypothyroidism;\n* Presenting or having a history of eating disorder (e.g. anorexia, food allergy) or gastro-intestinal malabsorption such as celiac disease, Crohn's disease, lactose intolerance;\n* Participant with an history of sleeve or bypass;\n* Participant with skin abnormalities (e.g., scars, excessive hair, tattooing) or any dermatosis (e.g., psoriasis, eczema, acne vulgaris) on the face which could interfere with the study;\n* Participant with history of any severe disease or current condition which, in the opinion of the Investigator would put the participant at risk by participating in the study or would interfere significantly with the evaluation of study results\n* Participant with known or suspected hypersensitivity to any ingredient(s) of the investigational products;\n* Participants having undergone any aesthetic procedures (such as chemical peels, laser treatments, dermabrasions, injections, anti-ageing masks, hair implants, etc.) on the test areas within 6 months prior to the start of the study are excluded.\n* Participant who, in the opinion of the investigator, is unlikely to comply with the Clinical Study Protocol (e.g., alcoholism, drug dependency or psychotic state);\n* Participant having use systemic corticosteroids, immunosuppressive drugs, or retinoids (oral or topical) within 3 months prior to study enrollment;\n* Only for participants (20 in each group) who are willing to accept skin microbiopsies: The participant who has a contraindication to skin biopsies\n* Participant impossible to contact in case of emergency;\n* Participant with current participation in any other interventional clinical study, based on interview of the Participant;\n* Participant who is in an exclusion period in the National Biomedical Research Register of the French Ministry of Health at randomization;\n* Participant who has been deprived of their freedom by administrative or legal decision, or who is under care of a guardian or legal guardianship, or Participant hospitalized in a medical or social establishment for any reason.","FEMALE","45 Years","60 Years",{"count":62,"type":22},165,"INTERVENTIONAL",[65],"NA","This clinical study is conducted at one study site and in 165 women with visible signs of skin aging. It compares after 13 weeks the benefit of a combined oral collagen supplement and topical collagen serum regimen compared with oral collagen alone and topical collagen serum alone in reducing in women presenting visible signs of skin ageing .",[68,69,27,70,71,72,73,74,75],"Visible Skin Aging Signs","Wrinkles and Folds in Lower Face","Skin Elasticity","Skin Firmness","Skin Evenness","Skin Radiance","Skin Smoothness","Skin Density","NOT_YET_RECRUITING","2026-03-11",{"date":79,"type":42},"2026-03-16",{"date":81,"type":22},"2026-03-15",{"date":83,"type":22},"2026-10-31",{"name":85,"class":86},"Vichy Laboratoires","INDUSTRY",{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":91,"acronym":92,"eligibilityCriteria":93,"healthyVolunteers":17,"sex":58,"minAge":94,"maxAge":60,"enrollmentInfo":95,"targetDuration":4,"studyType":63,"phases":97,"briefSummary":98,"conditions":99,"keywords":102,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":4},"100627891","examine-impact-of-topical-application-of-active-versus-placebo-on-the-skin-microbiome-in-sensitive-skin-100627891","NCT07454525","Examine Impact of Topical Application of Active Versus Placebo on the Skin Microbiome in Sensitive Skin.","SkinBiome","Inclusion Criteria:\n\n* Women aged 40-60 among all ethnicities and Fitzpatrick scale.\n* With self-assessed sensitive skin (SS10 \\> 13) and self-reported mild to moderate fine lines and wrinkles.\n* Must spend minimum 1 hour outside from 10am-4pm at least 5 times per week.\n* Residing within the same country on the mid to west coast (California, Nevada, Utah, Arizona, Colorado, New Mexico, Kansas, Oklahoma, Texas, Illinois, Kansas, Idaho, Nebraska, Montana).\n* Consider themselves to be in good health.\n* Willing to continue to use their current cosmetic products (foundation, blush, eyeshadow, sunscreen, etc.) and with the same routine\u002Ffrequency if they do not contain anti-aging ingredients.\n* Willing to refrain from using AHA, other peeling acids (PHA, BHA), prescription products such as retinoids or hydroquinone etc. during the study.\n* Willing to take skin swabs to support measures of the skin microbiome.\n* Must understand their role in the study, provide written informed consent, and fully participate over the 14-week period.\n* Willing to use the products provided within the study as instructed. Willing to change their current skincare routine and replace it with the given regimen for 14 weeks.\n* Willing to maintain diet and lifestyle (including physical exercise) during study period.\n\nExclusion Criteria:\n\n* Used any of the products to be tested in the claim study in the past 3 months. - Participation in a similar skin study within the past 30 days.\n* Have active skin disorders such as psoriasis, eczema, allergies, wounds, scars, or severe acne on their forehead.\n* Regular use of probiotic supplements\n* Consumption of fermented foods (including kefir, probiotic containing yoghurt, kombucha or other) for more than 5 times a week\n* Are orally or topically using or have used in the past 6 months: antibiotics, NSAIDS, antihistamines, immuno-suppressants, corticosteroids, prescription products such as retinoids, hydroquinone, or strong AHA treatments.\n* Have started hormonal treatment (e.g., contraceptives, fertility treatments, or HRT for menopause) within the past 3 months or in case they are on a treatment for more than 3 months they are unwilling to maintain a stable regimen for the duration of the study.\n* Pregnant or breastfeeding.\n* Any history of significant disease or medical condition to alter skin appearances such as type 2 diabetes, cancer, renal disorders or hepatic dysfunction.\n* Individuals who have had medical procedures in their face such as laser resurfacing (or any type of laser treatment ex. photo depilation), plastic surgery (including Botox) within the last 12 months or history of UV radiation (tanning and facial lamps) within the last 3 months.\n* Active Vitiligo or any other chronic skin conditions.\n* Individuals with any history that, in the investigator's opinion, indicates potential harm to the subject or could jeopardize the validity of the study.\n* History of poor cooperation, non-compliance, unreliability, or unwillingness to follow the research protocol and timeline.","40 Years",{"count":96,"type":22},45,[65],"The purpose of this study is to build insights to understand how the placebo and active impacts the skin microbiome in women with high skin sensitivity (SS10 \\> 13) and sun exposure. Microbiome samples will be taken at baseline after 2 weeks of using the placebo (base without active) as a run-in period followed by the usage of placebo for an additional 4 weeks. The participants will then start the usage of active formula for an additional 8 weeks with microbiome samples collected at the 10-week and 14-week. This will allow us to observe how the microbiome changes over time after the product usage of both placebo and active formulations relative to the pre-regimen condition. In addition, headshot photos will be taken using the Haut AI application at each time point concurrent to the microbiome sample collection to examine changes in skin appearances after the regimen.",[28,100,101,27],"Skin Microbiome","Skin Microbiota",[103,28,104,105,106,107,108],"Microbiome","Skin ageing","Fine lines","Face Skin","Sun exposure","Skin appearance","2026-03-04",{"date":111,"type":42},"2026-03-06",{"date":113,"type":22},"2026-02",{"date":115,"type":22},"2026-06",{"name":117,"class":86},"AB Biotics, SA",{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":124,"eligibilityCriteria":125,"healthyVolunteers":17,"sex":58,"minAge":126,"maxAge":60,"enrollmentInfo":127,"targetDuration":4,"studyType":63,"phases":128,"briefSummary":129,"conditions":130,"keywords":134,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":140,"leadSponsor":142,"locationsCount":4},"100619355","clinical-trial-to-assess-the-efficacy-and-safety-of-a-cosmetic-product-in-individuals-showing-signs-of-cutaneous-aging-100619355","NCT07343544","Clinical Trial to Assess the Efficacy and Safety of a Cosmetic Product in Individuals Showing Signs of Cutaneous Aging.","Estudio clínico Para Evaluar Los Efectos y la Seguridad de un Producto cosmético en Sujetos Con Signos de Envejecimiento cutáneo.","SkinMeter","Inclusion Criteria:\n\n* Female participants.\n* Age between 35 and 60 years.\n* All skin types (combination, oily, dry, and\u002For normal).\n* Skin condition: 50% sensitive skin and 50% normal skin.\n* Visible signs of facial skin aging (mild\u002Fmoderate wrinkles and\u002For pigmentation spots).\n* Willingness to participate voluntarily and provide written informed consent.\n* Ability to understand the study objectives and procedures.\n* Good general health (physical and mental).\n* Availability to attend all scheduled visits at the research center.\n* Discontinuation of anti-aging products on the experimental area (face) at least 7 days prior to study start.\n* Commitment not to change facial hygiene routines during the study.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women.\n* History of allergy to cosmetic products and\u002For dietary supplements.\n* Known allergy or hypersensitivity to any component of the product.\n* History or current diagnosis of cancer.\n* Active skin diseases or infections in the experimental area.\n* Recent or planned surgical or aesthetic interventions in the experimental area Medical-aesthetic treatments on the face within the last 6 months (e.g., botulinum toxin, hyaluronic acid, laser, radiofrequency, HIFU, deep chemical peels, microneedling with actives).\n* Relevant dermatological conditions in the experimental area (eczema, psoriasis, allergic\u002Fcontact dermatitis, etc.).\n* Use of topical or systemic medications affecting the skin (retinoids, antibiotics, corticosteroids) within the last 3 months.\n* Current or planned use of supplements that may affect skin health (collagen, antioxidant vitamins A\u002FC\u002FE, zinc, omega-3, oral probiotics\u002Fprebiotics).\n* Systemic diseases such as autoimmune disorders (rheumatoid arthritis, lupus, multiple sclerosis), chronic viral infections (HIV, hepatitis B\u002FC), or severe metabolic diseases.\n* Use of any product other than the study product on the experimental area during the study.\n* Planned significant changes in health habits during the study (diet, physical activity, structured exercise programs).\n* Recent or planned changes in hormonal contraceptives.\n* Sun or UVA exposure during the study.\n* Participation in another clinical study involving the same experimental area\n* Application of any product on the experimental area on the day of study initiation.\n* Any medical condition, at the investigator's discretion, that may interfere with protocol adherence or participant safety.","35 Years",{"count":96,"type":22},[65],"This clinical study investigates the effects and safety of a topical cosmetic product containing postbiotics (Bifida ferment extract and Pediococcus ferment extract) in women aged 35-60 with visible signs of skin aging.\n\nThe study is a 3-month, single-center, intra-subject controlled trial involving 45 Caucasian women with sensitive or normal skin. Participants will apply 1 ml of the product twice daily. Clinical evaluations will be conducted at baseline and at 1 month, 2 months, and 3 months, using validated dermatological scales and non-invasive instruments (AEVA3D, Mexameter®, MoistureMap®, Cutometer®, Tewameter®, Clarius®, Glossymeter®).\n\nSafety will be assessed through systematic monitoring of adverse events, with serious adverse events expected to remain below 1%. Subjective perception will be evaluated via structured questionnaires.",[28,27,131,132,133],"Fine Lines","Face Aging\u002FPhoto Aging of Moderate Grade","Face Skin Photoaging",[106,135,28,104],"Postbiotics","2026-01-08",{"date":138,"type":42},"2026-01-15",{"date":113,"type":22},{"date":141,"type":22},"2026-05",{"name":117,"class":86}]